BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 10915164)

  • 21. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
    Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
    Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New era of liver transplantation for hepatitis B: a 17-year single-center experience.
    Anselmo DM; Ghobrial RM; Jung LC; Weaver M; Cao C; Saab S; Kunder G; Chen PW; Farmer DG; Yersiz H; Baquerizo A; Geevarghese S; Han SH; Goldstein L; Holt CD; Gornbein JA; Busuttil RW
    Ann Surg; 2002 May; 235(5):611-9; discussion 619-20. PubMed ID: 11981206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
    Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
    Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.
    Rosenau J; Bahr MJ; Tillmann HL; Trautwein C; Klempnauer J; Manns MP; Böker KHW
    J Hepatol; 2001 Jun; 34(6):895-902. PubMed ID: 11451174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention and management of hepatitis B virus reinfection after liver transplantation].
    Ma Y; Tai Q; He XS; Wang GD; Hu AB
    Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1209-12. PubMed ID: 19781163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.
    Buti M; Mas A; Prieto M; Casafont F; González A; Miras M; Herrero JI; Jardí R; Cruz de Castro E; García-Rey C
    J Hepatol; 2003 Jun; 38(6):811-7. PubMed ID: 12763375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation].
    Zheng S; Wu J; Wang W; Huang D; Liang T; Lu A
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(7):445-8. PubMed ID: 12133511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of long-term administration of intravenous hepatitis B immunoglobulins for the prevention of recurrent hepatitis B after liver transplantation.
    Pauwelyn K; Cassiman D; Laleman W; Verslype C; Monbaliu D; Aerts R; Van Steenbergen W; Pirenne J; Nevens F
    Transplant Proc; 2010 Dec; 42(10):4399-402. PubMed ID: 21168707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue?
    van Nunen AB; de Man RA; Heijtink RA; Vossen AC; Schalm SW
    J Viral Hepat; 2002 May; 9(3):221-8. PubMed ID: 12010511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.
    Yoshida EM; Erb SR; Partovi N; Scudamore CH; Chung SW; Frighetto L; Eggen HJ; Steinbrecher UP
    Liver Transpl Surg; 1999 Nov; 5(6):520-5. PubMed ID: 10545541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
    Katz LH; Paul M; Guy DG; Tur-Kaspa R
    Transpl Infect Dis; 2010 Aug; 12(4):292-308. PubMed ID: 20002355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation.
    Wang ZX; Ding GS; Fu H; Zhang JJ; Chen XS; Guo WY; Shi XM; Fu ZR
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):345-8. PubMed ID: 15313666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.